Procedures
EGFR‐TKI failure, tumor, Tumor, Cancer
DISEASE PROGRESSION, ADVERSE EVENT, TUMOR, TUMOR, BLOOD, CANCER
The patients received platinum‐based chemotherapy followed by nivolumab maintenance therapy after EGFR‐TKI failure (Figure Imaging assessments, including computed tomography or magnetic resonance imaging, of the brain were performed every 6 weeks (±7 days) for 6 months, and then every 12 weeks (±14 days) until disease progression. Tumor response and progression were evaluated as per protocol until disease progression according to RECIST version 1.1.AEs were graded as per the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 and monitored throughout the study for 30 days after the last dose of nivolumab or until a new treatment was started, whichever occurred first.Blood samples were collected to assess the blood TMB before the first dosing of nivolumab and at the first tumor assessment. More than 10 mutations per mega‐base was defined as high TMB.